StockData
Genmab A/S logo

Genmab A/S

GMABNasdaqPharmaceutical PreparationsAlso trades as GNMSF
Financials through fiscal 2025, year ended Dec 31, 2025Score 0/30
$50.97−0.99 (-1.91%)

Close on Nov 18, 2026

Genmab A/S R&D Employees at Period-End (FTEs) by Quarter

Genmab A/S R&D Employees at Period-End (FTEs): 2,081 in Q3 2026, up 13.0% from a year earlier.

Latest, Q3 2026
2,081
Period ended Sep 30, 2026
Change on a year earlier
+13.0%
1,841 in Q3 2025
History
30 quarters
Since Q1 2019
Sources
27
Documents cited below

Where the Q3 2026 figure comes from

“|| Research and development employees | $ | 2,081 | $ | 1,841”

Source: Genmab Form 6-K — Q3 2026 Interim Report (Nine Months Ended Sep 30, 2026) ↗

Consolidated research, translational medicine, CMC, and clinical development FTEs (64.1% of total workforce as of Q3 2026).

quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedR&D Employees at Period-End (FTEs)Year on yearSource
Q3 2026Sep 30, 20262,081+13.0%Genmab Form 6-K — Q3 2026 Interim Report (Nine Months Ended Sep 30, 2026) ↗
Q2 2026Jun 30, 20262,056+12.3%Genmab Form 6-K — H1 / Q2 2026 Interim Report (Six Months Ended Jun 30, 2026) ↗
Q1 2026Mar 31, 20262,027+10.3%Genmab Form 6-K — Q1 2026 Interim Report (Three Months Ended Mar 31, 2026) ↗
Q4 2025Dec 31, 20252,089+10.8%Genmab Form 20-F — FY2025 Annual Report (Year Ended Dec 31, 2025) ↗
Q3 2025Sep 30, 20251,841-0.6%Genmab Form 6-K — Q3 2025 Interim Report (Nine Months Ended Sep 30, 2025) ↗
Q2 2025Jun 30, 20251,830+3.2%Genmab Form 6-K — H1 / Q2 2025 Interim Report (Six Months Ended Jun 30, 2025) ↗
Q1 2025Mar 31, 20251,837+14.7%Genmab Form 6-K — Q1 2025 Interim Report (Three Months Ended Mar 31, 2025) ↗
Q4 2024Dec 31, 20241,886+22.4%Genmab Form 20-F — FY2024 Annual Report (Year Ended Dec 31, 2024) ↗
Q3 2024Sep 30, 20241,853+24.9%Genmab Form 6-K — Q3 2024 Interim Report (Nine Months Ended Sep 30, 2024) ↗
Q2 2024Jun 30, 20241,774+27.1%Genmab Form 6-K — H1 / Q2 2024 Interim Report (Six Months Ended Jun 30, 2024) ↗
Q1 2024Mar 31, 20241,601+23.8%Genmab Form 6-K — Q1 2024 Interim Report (Three Months Ended Mar 31, 2024) ↗
Q4 2023Dec 31, 20231,541+29.2%Genmab Form 20-F — FY2023 Annual Report (Year Ended Dec 31, 2023) ↗
Q3 2023Sep 30, 20231,484+31.4%Genmab Form 6-K — Q3 2023 Interim Report (Nine Months Ended Sep 30, 2023) ↗
Q2 2023Jun 30, 20231,396+33.0%Genmab Form 6-K — H1 / Q2 2023 Interim Report (Six Months Ended Jun 30, 2023) ↗
Q1 2023Mar 31, 20231,293+35.5%Genmab Form 6-K — Q1 2023 Interim Report (Three Months Ended Mar 31, 2023) ↗
Q4 2022Dec 31, 20221,193+28.7%Genmab Form 20-F — FY2022 Annual Report (Year Ended Dec 31, 2022) ↗

Cite this data

StockData. (2026). Genmab A/S R&D Employees at Period-End (FTEs), quarterly Q1 2019–Q3 2026 [Data set]. Compiled from Genmab A/S SEC filings and investor materials. https://stockdatahq.com/stocks/gmab/kpis/fte-rd

See every metric in the Genmab A/S KPI table. Data updated Nov 11, 2026.

See a number that looks wrong?